Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03719326 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies
A Phase 1 study, sponsored by Arcus Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT03719326 is a Phase 1 study that has completed, run by Arcus Biosciences. The registered enrollment target is 35 participants.
The verdict
NCT03719326, a Phase 1 study, has completed, sponsored by Arcus Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
This is a Phase 1/1b, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical activity of etrumadenant (AB928) in combination with pegylated liposomal doxorubicin (PLD) with or without IPI-549 in participants with advanced metastatic triple-negative breast cancer (TNBC) or ovarian cancer, and etrumadenant in combination with nanoparticle albumin-bound-paclitaxel (NP) in participants with advanced metastatic TNBC.
Interventions
- DRUG Etrumadenant
- DRUG Pegylated liposomal doxorubicin (PLD)
- DRUG IPI-549
- DRUG nanoparticle albumin-bound paclitaxel (NP)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2018-10-15 |
| Est. Completion | 2021-07-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03719326
The ClinicalTrials.gov registry entry for NCT03719326 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arcus Biosciences, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Etrumadenant is the first listed.
NCT03719326 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03719326 about?
NCT03719326 is a clinical study titled "A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies". This is a Phase 1/1b, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical activity of etrumadenant (AB928) in combination with pegylated liposomal doxorubicin (PLD) with or without IPI-549 in participant...
What is the current status of trial NCT03719326?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2018-10-15. Estimated completion is 2021-07-02.
What interventions are being tested in trial NCT03719326?
The interventions under investigation include: Etrumadenant (DRUG), Pegylated liposomal doxorubicin (PLD) (DRUG), IPI-549 (DRUG), nanoparticle albumin-bound paclitaxel (NP) (DRUG).
Who is sponsoring clinical trial NCT03719326?
This trial is sponsored by Arcus Biosciences, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.